Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $108.1111.

A number of equities analysts have weighed in on the stock. Leerink Partners set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Mizuho dropped their price target on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. William Blair set a $102.50 price objective on shares of Lantheus in a report on Monday, August 3rd. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $125.00 to $102.50 in a research note on Monday, August 3rd.

Institutional Trading of Lantheus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP purchased a new stake in Lantheus during the 2nd quarter worth about $290,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Lantheus during the 2nd quarter valued at about $1,002,000. California State Teachers Retirement System increased its position in shares of Lantheus by 10,684.5% during the second quarter. California State Teachers Retirement System now owns 8,434,214 shares of the medical equipment provider’s stock valued at $935,692,000 after buying an additional 8,356,007 shares during the period. AlphaGrep UK Ltd bought a new stake in shares of Lantheus during the second quarter valued at about $408,000. Finally, Three Seasons Wealth LLC lifted its holdings in shares of Lantheus by 13.6% in the second quarter. Three Seasons Wealth LLC now owns 15,333 shares of the medical equipment provider’s stock worth $1,701,000 after buying an additional 1,838 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH opened at $100.97 on Friday. Lantheus has a 1 year low of $49.67 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The stock’s fifty day moving average price is $103.12 and its two-hundred day moving average price is $92.74. The firm has a market cap of $6.59 billion, a PE ratio of 24.39 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same quarter in the prior year, the company earned $1.57 EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, equities research analysts forecast that Lantheus will post 4.5 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.